Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: A phase 2 trial (KDOG 0501-P2)

International Journal of Radiation Oncology Biology Physics

Volumn 89, Issue 4, 2014, Pages 872-879

  Higuchi, Katsuhiko ^a   Komori, Shouko ^b   Tanabe, Satoshi ^a   Katada, Chikatoshi ^b   Azuma, Mizutomo ^a   Ishiyama, Hiromichi ^b   Sasaki, Tohru ^a   Ishido, Kenji ^a   Katada, Natsuya ^b   Hayakawa, Kazushige ^b   Koizumi, Wasaburo ^a  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMORADIOTHERAPY; DISEASES; PLATINUM COMPOUNDS; TOXICITY;

CHEMORADIATION THERAPIES; CONFIDENCE INTERVAL; ESOPHAGEAL CANCER; LYMPH NODE METASTASIS; METHODS AND MATERIALS; PERFORMANCE STATUS; PROGRESSION FREE SURVIVAL; TOTAL RADIATION DOSE;

RADIOTHERAPY;

CISPLATIN; CREATININE; DOCETAXEL; FLUOROURACIL;

ADULT; ADVANCED CANCER; ADVANCED ESOPHAGEAL CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; AORTA ANEURYSM; ARTICLE; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS FISTULA; ESOPHAGUS STENOSIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS; FEASIBILITY STUDIES; FEBRILE NEUTROPENIA; FEMALE; FLUOROURACIL; HUMANS; LEUKOPENIA; LYMPHATIC IRRADIATION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; RADIOTHERAPY DOSAGE; TAXOIDS;

EID: 84903266598     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.03.030     Document Type: Article

References (28)

1. T.N. Walsh, N. Noonan, and D. Hollywood et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma N Engl J Med 335 1996 462 467
2. D.P. Kelsen, R. Ginsberg, and T.F. Pajak et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer N Engl J Med 339 1998 1979 1984
3. J.S. Cooper, M.D. Guo, and A. Herskovic et al. Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group JAMA 281 1999 1623 1627
4. B.D. Minsky, T.F. Pajak, and R.J. Ginsberg et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy J Clin Oncol 20 2002 1167 1174
5. L. Bedenne, P. Michel, and O. Bouche et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102 J Clin Oncol 25 2007 1160 1168
6. M. Stahl, M. Stuschke, and N. Lehmann et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus J Clin Oncol 23 2005 2310 2317
7. A. Ohtsu, N. Boku, and K. Muro et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus J Clin Oncol 17 1999 2915 2921
8. K. Ishida, N. Ando, and S. Yamamoto et al. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: A Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516) Jpn J Clin Oncol 34 2004 615 619
9. J.R. Rigas, K.H. Dragnev, and J.A. Bubis Docetaxel in the treatment of esophageal cancer Semin Oncol 32 2005 S39 S51
10. A.I. Einzig, D. Neuberg, and S.C. Remick et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The Eastern Cooperative Oncology Group (ECOG) results of protocol E1293 Med Oncol 13 1996 87 93
11. K. Muro, T. Hamaguchi, and A. Ohtsu et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer Ann Oncol 15 2004 955 959
12. D.H. Ilson, J. Ajani, and K. Bhalla et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus J Clin Oncol 16 1998 1826 1834
13. A.L. Dunne, C. Mothersill, and T. Robson et al. Radiosensitization of colon cancer cell lines by docetaxel: Mechanisms of action Oncol Res 14 2004 447 454
14. E.K. Rowinsky, and R.C. Donehower Paclitaxel (taxol) N Engl J Med 332 1995 1004 1014
15. K Higuchi, W Koizumi, and S. Tanabe et al. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501) Radiother Oncol 87 2008 398 404
16. P. Therasse, S. Arbuck, and E. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
17. H. Kuwano, Y. Nishimura, and A. Ohtsu et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2007 edition Esophagus 5 2008 61 73
18. S. Ishikura, K. Nihei, and A. Ohtsu et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus J Clin Oncol 21 2003 2697 2702
19. K. Kato, K. Muro, and K. Minashi et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906) Int J Radiat Oncol Biol Phys 81 2011 684 690
20. M. Shinoda, N. Ando, and H. Kato et al. A multicenter randomized phase II (rPII)/III study comparing concurrent chemoradiotherapy (CRT) with low-dose cisplatin plus continuous infusion of 5-fluorouracil (LDPF) and standard-dose PF (SDPF) for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus (JCOG0303) [Abstract 4053] J Clin Oncol 28 suppl 2010 15s
21. F. Pasini, G. de Manzoni, and A. Zanoni et al. Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: A phase 2 study Cancer 119 2013 939 945
22. A. Zanoni, G. Verlato, and S. Giacopuzzi et al. Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center Ann Surg Oncol 20 2013 1993 1999
23. D.R. Spigel, F.A. Greco, and A.A. Meluch et al. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction J Clin Oncol 28 2010 2213 2219
24. T. Crosby, C.N. Hurt, and S. Falk et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): A multicentre, phase 2/3 randomised trial Lancet Oncol 14 2013 627 637
25. M. Onozawa, K. Nihei, and S. Ishikura et al. Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus Radiother Oncol 92 2009 266 269
26. H. Yamashita, K. Okuma, and R. Wakui et al. Details of recurrence sites after elective nodal irradiation (ENI) using 3D-conformal radiotherapy (3D-CRT) combined with chemotherapy for thoracic esophageal squamous cell carcinoma-a retrospective analysis Radiother Oncol 98 2011 255 260
27. M. Al-Sarraf, K. Martz, and A. Herskovic et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study J Clin Oncol 15 1997 277 284
28. M.A. Shah, S. Shibata, and R.G. Stoller et al. Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE) [Abstract 4014] J Clin Oncol 28 suppl 2010 15s